Dr. Reddy’s Laboratories Limited (Dr. Reddy’s) is a global pharmaceutical company. The Company operates in three segments: Pharmaceutical Services and Active Ingredients (PSAI), which includes active pharmaceutical ingredients and intermediaries, which are the principal ingredients for finished pharmaceutical products; Global Generics, which consists of finished pharmaceutical products ready for consumption by the patient, and Proprietary Products, which involves the discovery of new chemical entities for subsequent commercialization and out-licensing. Dr. Reddy’s is vertically integrated and uses its pharmaceutical ingredients and intermediates in its own finished dosage products. The Company conducts basic research mainly in the areas of metabolic disorders, cardiovascular diseases and bacterial infection. On July 30, 2008, it acquired 85.69% interest in Perlecan Pharma Private Limited (Perlecan Pharma). Subsequently Perlecan Pharma became a wholly owned subsidiary of the Company.

Oxagen is focused on becoming a significant biopharmaceutical company, developing a pipeline of novel drugs to treat inflammatory diseases. The Company has created a portfolio of valuable drug targets centered on the highly attractive class of receptors, GPCRs. Through its heritage in human genetics, Oxagen has validated a number of GPCR targets, many of them novel, and selected the most promising as drug targets.Oxagen was established in April 1997 and initially focused on identifying drug targets through genetics. Since 2003 the Company has focused on building a drug discovery and development capability and pipeline around GPCR targets. Oxagen’s lead compound OC000459 is a novel oral anti-inflammatory agent for the treatment of allergic disease and has successfully completed Phase IIa trials demonstrating efficacy in both asthma and allergic rhinitis. Phase IIb dose-range finding studies are currently underway. The Company is based in Milton Park, south of Oxford.

Purely Proteins doesn't mix your ordinary protein shake. Through its proprietary technology, the company purifies human proteins to accelerate biotherapeutic drug discovery and drug screening. Purely Proteins also operates a subscription-based online database of gene and protein information called TargetBASE, which gives chemists and biologists a summary of known and potential protein targets that may help in the discovery of therapies for diabetes, cancer, and Alzheimer's disease. The company conducts its research in conjunction with several business partners, including Abcam Ltd, Asahi Kasei, Cytomyx Limited, and Inhibox Ltd. CEO David Parry-Smith co-founded Purely Proteins in 2002.

Pathwork Diagnostics is hoping to offer doctors the ability to predict which diseases a patient may have. The company is developing methods to identify biomarker patterns that indicate certain types of diseases. Many tests cannot identify diseases in their early forms. Pathwork Diagnostics is working on identifying the earliest possible signs of a given disease, such as cancer, to help doctors determine the best therapies to treat that disease. The company was founded in 2002. Investment firms Advent Venture, Prospect Venture, and Versant Ventures are the largest shareholders.

Essential Nutrition Ltd. was founded in 1989. Essential Nutrition offers research, testing, and manufacturing services to drug companies. The UK-based firm estimates its manufacturing capacity to be up to 8.5 million tablets per day. The company also produces its own brand of health food supplements which it markets online. It partners with various agronomy firms to determine optimum location and growth cycles for its herbal medicine crops, and it has developed nutritional research with universities throughout the UK and US. Essential Nutrition is family owned and operated.

Neptune Technologies & Bioressources harvests krill (tiny deepwater crustaceans that resemble shrimp) from the ocean and processes it into value-added bioactive ingredients including polyunsaturated fatty acids and antioxidants. These 'Neptune Krill Oil'-based products are used in cosmetics and nutritional supplements as an alternative to vegetable oils. The company's Neptune Krill Aquatein is a marine protein concentrate also used in nutritional supplements. Neptune Technologies intends to penetrate the biopharmaceutical industry, using its marine oil extracts as a medicinal base.

Eisai Inc. develops and markets pharmaceuticals to treat a variety of ills. As the US pharmaceutical production arm of Eisai Co., its current product roster includes Alzheimer's treatment Aricept, Aciphex for acid reflux, anticoagulant Fragmin, and anti-convulsant Zonegran. It also maintains an extensive pipeline of potential drugs to address cancer, epilepsy, and severe infection. Subsidiaries Eisai Research Institute of Boston and Eisai Medical Research conduct drug development efforts in areas including oncology, neurology, and gastrointestinal ailments.

Ash Stevens, Inc. was founded in 1962 to provide chemical research for the government and later branched out into the private sector. Ash Stevens, Inc. company, a contract pharmaceutical manufacturer develops and manufactures active pharmaceutical ingredients (APIs) for other pharmaceutical companies. It also supports clinical drug trials and helps others navigate the FDA's regulatory maze. Its customers include the federal government and commercial pharmaceutical firms. The company's portfolio includes about a dozen FDA-approved drug components.

NexMed, Inc. was founded in 1987 and is based in San Diego, California. NexMed, Inc. is a pharmaceutical and medical technology company with a focus on developing and commercializing therapeutic products based on its delivery systems. The Company focuses its efforts on new and topical pharmaceutical products based on a penetration enhancement drug delivery technology known as NexACT, which may enable an active drug to be better absorbed through the skin. The NexACT transdermal drug delivery technology is designed to enhance the absorption of an active drug through the skin, overcoming the skin’s natural barrier properties, and enabling high concentrations of the active drug to rapidly penetrate the desired site of the skin or extremity. In December 2009, the Company closed its acquisition of Bio-Quant, Inc., a research organization for in vitro and in vivo contract drug discovery and pre-clinical development services.

Actelion Pharmaceuticals UK is the British arm of Swiss biotech firm Actelion. The drug manufacturer's product pipeline is based on its research of the endothelium, the single layer of cells between blood vessels and the blood that flows through them. Its first products are Tracleer for the treatment of pulmonary arterial hypertension, and Zavesca which is used to treat Type 1 Gaucher disease.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.